Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8455594 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP2D6APEX1PMP22TP53 | |
| SCHEMBL8201385 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP2D6APEX1PMP22TP53 | |
| SCHEMBL8855721 | 0.83 | TSHR (0.39) | TP53TSHRCYP3A4SLC6A4SLC7A5 | |
| SCHEMBL9498462 | 0.81 | CYP3A4 (0.42) | TP53TSHRCYP3A4SLC6A4SLC7A5 | |
| SCHEMBL6670843 | 0.81 | HRH3 (0.48) | — | |
| SCHEMBL2269394 | 0.81 | CYP3A4 (0.42) | TP53TSHRCYP3A4SLC6A4SLC7A5 | |
| SCHEMBL6670839 | 0.81 | HRH3 (0.48) | — | |
| SCHEMBL242931 | 0.81 | CYP3A4 (0.42) | TP53TSHRCYP3A4SLC6A4SLC7A5 | |
| SCHEMBL9503518 | 0.79 | CA2 (0.41) | TP53TSHRSLC6A4 | |
| SCHEMBL1972358 | 0.79 | TAAR1 (0.40) | CYP1A2TP53TSHRIDO1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | CYP1A2 140/4885CYP2D6 101/4885APEX1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.